

L10 ANSWER 4 OF 10 CAPLUS COPYRIGHT 1999 ACS
 AN 1994:570550 CAPLUS
 DN 121:170550
 TI Method using Staphylococcus **enterotoxin B** for treating
autoimmune diseases
 IN Ochi, Atsuo
 PA Mount Sinai Hospital Corp., Can.
 SO Can. Pat. Appl., 81 pp.
 CODEN: CPXXEB
 DT Patent
 LA English
 IC ICM A61K039-085
 CC 1-7 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2084120	AA	19940531	CA 1992-2084120	19921130
AB	A method of treating autoimmune diseases (multiple sclerosis, rheumatoid arthritis, etc.) assocd. with a predominance of T-cells expressing V.beta.8+ T-cell receptor comprises administering an amt. of Staphylococcus enterotoxin B (SEB) (or a deriv., analog, or active fragment thereof) effective to reduce the no. and/or inactivate T-cells expressing V.beta.8+ T-cell receptor whereby there is a decrease in disease activity. Methods are also claimed for using SEB to assay for T-cells expressing the V.beta.8+ T-cell receptor assocd. with autoimmune disease pathogenesis and for using SEB to down-regulate lymphokines (preferably tumor necrosis factor and/or interleukin-6).				
ST	Staphylococcus enterotoxin B autoimmune disease treatment; T cell autoimmune disease enterotoxin B				
IT	Deoxyribonucleic acids RL: BIOL (Biological study) (antibody to, redn. of, enterotoxin B of Staphylococcus in, autoimmune disease treatment in relation to)				
IT	Immune tolerance (autoimmune disease treatment with enterotoxin B of Staphylococcus in relation to)				
IT	Lymphokines and Cytokines RL: BIOL (Biological study) (enterotoxin B of Staphylococcus for down-regulation of)				
IT	Antidiabetics and Hypoglycemics (enterotoxin B of Staphylococcus, for type I diabetes, V.beta.8+ TCR-expressing T-cell inhibition in relation to)				
IT	Staphylococcus (enterotoxin B of, autoimmune disease treatment with, V.beta.8+ TCR-expressing T-cell inhibition in relation to)				
IT	Autoimmune disease Lupus erythematosus				